Anti-EIF2S1 (phospho S51) antibody [E90] (Ab32157)
EIF2A, EIF2S1, Eukaryotic translation initiation factor 2 subunit 1, Eukaryotic translation initiation factor 2 subunit alpha, eIF-2-alpha, eIF-2A, eIF-2alpha, eIF2-alpha
详细信息
背景信息
Anti-EIF2S1 (phospho S51) antibody [E90] (ab32157) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Dot Blot, IHC-P and WB. Anti-EIF2S1 (phospho S51) antibody [E90] (ab32157) was first used in a scientific publication in 1987 and has been cited over 274 times in peer reviewed journals. It's performance in Western Blot in human and mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-EIF2S1 (phospho S51) antibody [E90] (ab32157) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-EIF2S1 (phospho S51) antibody [E90] (ab32157) has 24 independent reviews from customers. Anti-EIF2S1 (phospho S51) antibody [E90] (ab32157) specifically detects EIF2S1 Phospho-S51 (UniProt ID: P05198; Molecular weight: 37kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone E90 - ab214434. Highly-cited antibody with >350 citations. Highly specific phospho S51 EIF2S1 antibody, essential for researchers studying eukaryotic initiation factor 2 subunit 1 and protein synthesis. This antibody is crucial in stress response research, particularly in understanding translation regulation and EIF2S1 phosphorylation. It is widely used in studies of cellular stress and EIF2S1 inhibitors Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.
文献引用 (343)
Context-dependent translation inhibition as a cancer therapeutic modality.
上下文依赖性翻译抑制作为一种癌症治疗方式。
ZAP targets aberrant mRNA transcripts encoding proteins with defective signal peptides for degradation.
ZAP 靶向降解编码具有缺陷信号肽的蛋白质的异常 mRNA 转录本。
Pharmacological Enhancement of Integrated Stress Response Confers Protection in Calcific Aortic Valve Disease.
药物增强综合应激反应可对钙化性主动脉瓣疾病起到保护作用。
METTL18 ensures pancreatic function by maintaining proper translation and proteostasis.
METTL18 通过维持正常的翻译和蛋白质稳态来确保胰腺功能。
RK-33 inhibits the OC43 coronavirus and induces stress granules via DDX3X-independent mechanisms.
RK-33 抑制 OC43 冠状病毒,并通过不依赖于 DDX3X 的机制诱导应激颗粒。
Selective antitumor and apoptosisâinducing effects of the Src inhibitor PP1 in human tongue squamous cell carcinoma cells.
Src抑制剂PP1对人舌鳞状细胞癌细胞的选择性抗肿瘤和凋亡诱导作用。
Crocin Protects Against Retinal Ischemia-Reperfusion Injury via Regulating Sirt6-Mediated Nrf2/HO-1 Pathway in Rats.
藏红花素通过调节 Sirt6 介导的 Nrf2/HO-1 通路保护大鼠免受视网膜缺血再灌注损伤。
Sephin1 alleviates white matter injury by protecting oligodendrocyte after intracerebral hemorrhage.
Sephin1 通过在脑出血后保护少突胶质细胞来减轻白质损伤。
Identification of ADAR1i-124: The first effective A-to-I RNA editing inhibitor with promising cancer therapeutic potential.
ADAR1i-124 的发现:首个具有良好抗癌潜力的有效 A-to-I RNA 编辑抑制剂。
- 1
- 2
- 3
- 4
- 5
- 6
- 35